ReviewerRepresentationEmploymentConsultantSpeakers BureauOwnership/Partnership/PrincipalPersonal ResearchInstitutional, Organizational, or Other Financial BenefitExpert Witness
Ralph G. BrindisOfficial Reviewer—ACC/AHA Task Force on Clinical Practice GuidelinesUniversity of California—Clinical Professor of Medicine
  • ACC

  • FDA CV Device Panel

NoneNone
  • State of California OSHPD

NoneNone
David C. Goff, Jr.Official Reviewer—AHAWake Forest University Public Health Sciences Internal Medicine—ProfessorNoneNoneNone
  • NIH

  • AHA

  • Colorado School of Public Health

None
Edward P. HavranekOfficial Reviewer—AHADenver Health Medical Center—Cardiologist
  • AHA

  • NHLBI

  • PCORI

NoneNoneNoneNoneNone
Robert C. HendelOfficial Reviewer—ACC Board of TrusteesUniversity of Miami Cardiac Imaging and Outpatient Services—Director
  • Adenosine Therapeutics

  • Astellas Pharma

NoneNoneNoneNoneNone
Srinivas MuraliOfficial Reviewer—ACC Board of GovernorsAllegheny Health Network—Director, Cardiovascular Institute
  • Actelion

  • Bayer

  • Actelion

None
  • Cardiokinetics

  • CVRx

  • Gilead

  • Actelion

  • Lung, LLC

  • Bayer

NoneNone
John A. SpertusOfficial Reviewer—AHASaint Luke’s Mid America Heart Institute—Director, Health Outcomes Research; University of Missouri-Kansas City—Professor
  • Amgen

  • Bayer

  • Copyright for SAQ, KCCQ, and PAQ

  • Janssen Pharmaceuticals

  • Novartis

  • Regeneron

  • United Healthcare (Scientific Advisory Board)

None
  • Health Outcomes Sciences

  • ACC

  • AHA

  • Lilly

  • Gilead Sciences

NoneNone

This table represents the relationships of reviewers with industry and other entities that were disclosed at the time of peer review, including those not deemed to be relevant to this document. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5,000 of the fair market value of the business entity, or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships that exist with no financial benefit are also included for the purpose of transparency. Names are listed in alphabetical order.

ACC indicates American College of Cardiology; AHA, American Heart Association; CV, cardiovascular; FDA, U.S. Food and Drug Administration; KCCQ, Kansas City Cardiomyopathy Questionnaire; NHLBI, National Heart, Lung, and Blood Institute; NIH, National Institutes of Health; OSHPD, Office of Statewide Health Planning and Development; PAQ, Peripheral Artery Questionnaire; PCORI, Patient-Centered Outcomes Research Institute; SAQ, Seattle Angina Questionnaire.

  • Significant relationship.

  • No financial benefit.